ACE and atrial fibrillation: For example, in the ARISTOTLE trial, 50%, 68%, and 77% of obese AF patients were treated with statins, beta‐blockers and ACE‐inhibitors, compared to 34%, 56%, and 61% of normal BMI patients, respectively.8